Androgen Deprivation Therapy News and Research

RSS

Long-term prostate cancer treatment study informs decisions for diverse groups

A 10-year follow up study of nearly 2,500 U.S. men who received prostate cancer treatment will help inform decision making in terms of treatments and side effects for a diverse population.

23 Jan 2024

Rutgers researchers devise strategy to boost prostate cancer treatment efficacy

Rutgers researchers can predict which patients will benefit from a popular prostate cancer drug – and have devised a strategy that may make the treatment work longer.

22 Jan 2024

New study unlocks hope for immunotherapy in metastatic prostate cancer

Immunotherapy has been disappointing as a prostate cancer treatment, but a new Columbia study suggests that the powerful treatments have potential when the disease starts to spread.

12 Dec 2023

Study finds racial disparity in the utilization of crucial prostate cancer therapy

A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found Black men diagnosed with more advanced stages of prostate cancer are significantly less likely to be prescribed novel hormone therapy than other racial and ethnic groups – including white or Latino men – despite the therapy being proven to effectively control the growth of prostate tumors and extend the lives of men with the disease.

1 Dec 2023

Docetaxel improves survival in men with high-grade prostate cancer and low PSA

Men with high-grade prostate cancer and low prostate-specific antigen (PSA) levels have a poor prognosis.

1 Nov 2023

Scientists identify two promising new treatment options for men with recurrent prostate cancer

Cedars-Sinai Cancer investigators have identified two promising new treatment options for men with recurrent prostate cancer-; both of which helped patients live longer without their disease progressing than the current standard treatment.

18 Oct 2023

New treatment approach effectively treats the most aggressive forms of prostate cancer

Researchers at the University of Chicago Medicine Comprehensive Cancer Center established "proof-of-concept" for a new treatment approach that was able to effectively treat the most aggressive forms of prostate cancer. The treatment showed complete tumor control and long-lasting survival without side effects in a mouse model of advanced prostate cancer.

19 Sep 2023

Study challenges the use of biochemical recurrence as prostate cancer predictor

A UCLA-led study found treatments that reduce the risk of being diagnosed with a cancer recurrence based on rising prostate-specific antigen (PSA) levels after radiotherapy, commonly referred to as biochemical recurrence, do not necessarily improve a patient's long-term overall survival.

28 Aug 2023

Androgen deprivation therapy increases the risk of depression, dementia, Alzheimer’s disease, and Parkinson’s disease

The association between Androgen Deprivation Therapy (ADT) and the risk of dementia.

16 Aug 2023

Copy number profiling provides insight as to why prostate cancer may become lethal

Researchers performed genome-wide copy number profiling of the androgen receptor (AR) on metastases from deceased prostate cancer patients.

16 Aug 2023

Researchers validate first-ever AI biomarker for ADT benefit in prostate cancer

Data from a new study published in NEJM Evidence shows promise for personalized use of short-term ADT in men with predominantly intermediate-risk prostate cancer.

30 Jun 2023

Study investigates whether metformin mitigates androgen deprivation therapy-related metabolic syndrome

A new research paper was published in Oncotarget's Volume 14 on June 19, 2023, entitled, "Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer."

21 Jun 2023

Phase 3 studies for rectal, brain, and kidney cancers to be presented by Dana-Farber researchers at ASCO 2023

Several phase 3 studies conducted by researchers from Dana-Farber Cancer Institute show promising results for patients with rectal, brain, and kidney cancers. The results of these studies, along with dozens of others led by Dana-Farber researchers, will be presented at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

26 May 2023

Declining PSA levels predict improved survival rates in men with non-metastatic castration-resistant prostate cancer

Declines in prostate-specific antigen (PSA) level after treatment with the next-generation androgen receptor inhibitor drug enzalutamide predict improved survival rates in men with non-metastatic castration-resistant prostate cancer (nmCRPC), reports The Journal of Urology, an Official Journal of the American Urological Association.

10 Feb 2023

Rising Medicare costs linked to increased use of new prostate cancer therapies

Medicare costs for treatment of metastatic prostate cancer have risen sharply within the last 15 years – reflecting increased use of new medications under Medicare Part D, reports a study in Urology Practice, an Official Journal of the American Urological Association.

20 Dec 2022

Study shows benefits of metastasis-directed therapy without ADT for oligorecurrent prostate cancer

For patients with solitary metastases from prostate cancer, an approach called metastasis-directed therapy (MDT) – focused treatment using surgery or radiation therapy, without androgen deprivation therapy (ADT) – can slow the time to cancer progression, reports a study in The Journal of Urology, an Official Journal of the American Urological Association

10 Nov 2022

Androgen Deprivation Therapy News and Research

Long-term prostate cancer treatment study informs decisions for diverse groups

Rutgers researchers devise strategy to boost prostate cancer treatment efficacy

New study unlocks hope for immunotherapy in metastatic prostate cancer

Study finds racial disparity in the utilization of crucial prostate cancer therapy

Docetaxel improves survival in men with high-grade prostate cancer and low PSA

Scientists identify two promising new treatment options for men with recurrent prostate cancer

New treatment approach effectively treats the most aggressive forms of prostate cancer

Study challenges the use of biochemical recurrence as prostate cancer predictor

Androgen deprivation therapy increases the risk of depression, dementia, Alzheimer’s disease, and Parkinson’s disease

Copy number profiling provides insight as to why prostate cancer may become lethal

Researchers validate first-ever AI biomarker for ADT benefit in prostate cancer

Study investigates whether metformin mitigates androgen deprivation therapy-related metabolic syndrome

Phase 3 studies for rectal, brain, and kidney cancers to be presented by Dana-Farber researchers at ASCO 2023

Declining PSA levels predict improved survival rates in men with non-metastatic castration-resistant prostate cancer

Rising Medicare costs linked to increased use of new prostate cancer therapies

Study shows benefits of metastasis-directed therapy without ADT for oligorecurrent prostate cancer

$38,398 for a single shot of a very old cancer drug

Clinical trial confirms the safety, efficacy of shortened radiation therapy for high-risk prostate cancer patients

Is male hypogonadism a risk factor for hospitalization for COVID-19?

How does COVID-19 affect sexual and bladder functions in men?

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News